eli lilly retatrutide press release 2024 2025 clinical trial results weight loss Retatrutide: A Promising Option for Non just released impressive – Retatrutide, Eli Lilly's next obesity

It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that when overactive, consumes excessive NAD+ and impairs cellular energy metabolism

Marissa Liza: So that was what, you know, when I thought about if I were to give this to a patient or who I thought potentially could benefit from this based on how I feel after taking it

Elevated plasma homocysteine level in vascular dementia reflects the vascular disease process

Patients need: Nutrition Behavior change Strength & movement Long-term lifestyle support In other words they need a team

However, they can also trigger side effects, including changes to hair and skin quality

That gap matters, but 15% weight loss still represents a transformative result for most people